Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04634552 · ClinicalTrials.gov registry record · Phase 2
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
A Phase 2 study of Hematological Malignancies, sponsored by Janssen Research & Development.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 510
- Enrollment target
- 20
- Study locations
NCT04634552 is a Phase 2 study of Hematological Malignancies that is actively recruiting participants, run by Janssen Research & Development. The registered enrollment target is 510 participants, below the 745-participant average among 16 other Hematological Malignancies trials with a reported enrollment target (32% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT04634552, a Phase 2 study of Hematological Malignancies, is actively recruiting participants, sponsored by Janssen Research & Development.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 510 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of talquetamab in participants with relapsed or refractory multiple myeloma at the recommended Phase 2 dose(s) (RP2Ds) (Part 3).
Conditions Studied
Interventions
- DRUG Talquetamab
Study Locations (20)
Other
- UZ Antwerpen - Edegem
- UZ Leuven - Leuven
- CHU de Liège - Domaine Universitaire du Sart Tilman - Liège
- UCL - Saint Luc - Woluwe-Saint-Lambert
- Peking University Third Hospital - Beijing
- Sun Yat Sen University Cancer Center - Guangzhou
New York
- NYU Langone Health - New York
- Mount Sinai Medical Center - New York
- University of Rochester Medical Center - Rochester
Alabama
- University of Alabama Birmingham - Birmingham
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
California
- City of Hope - Duarte
Florida
- Memorial Healthcare System - Hollywood
Georgia
- Emory University Winship Cancer Institute - Atlanta
Illinois
- University of Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 510 participants |
| Start Date | 2021-02-01 |
| Est. Completion | 2029-03-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04634552
The ClinicalTrials.gov registry entry for NCT04634552 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 510 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 745-participant average among 16 other Hematological Malignancies trials with a reported enrollment target (32% lower). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hematological Malignancies appearing as the primary indexed condition, and to 1 intervention - of which Talquetamab is the first listed.
NCT04634552 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Other, New York, Alabama.
Frequently Asked Questions
What is clinical trial NCT04634552 about?
NCT04634552 is a clinical study titled "A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma". The purpose of this study is to evaluate the efficacy and safety of talquetamab in participants with relapsed or refractory multiple myeloma at the recommended Phase 2 dose(s) (RP2Ds) (Part 3).
What is the current status of trial NCT04634552?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 510 participants. The study started on 2021-02-01. Estimated completion is 2029-03-30.
What conditions does trial NCT04634552 study?
This clinical trial studies the following conditions: Hematological Malignancies.
What interventions are being tested in trial NCT04634552?
The interventions under investigation include: Talquetamab (DRUG).
Who is sponsoring clinical trial NCT04634552?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04634552 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematological Malignancies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation
RECRUITING · Phase 2
-
A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004)
COMPLETED · Phase 2
-
A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies
RECRUITING · Phase 1
-
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
RECRUITING
-
Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCT
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.